2026
conference-abstract
OpenAlex
Traci L. Hilton, Ryan Meng, Guo Hui Gan, Tarsem Lal Moudgil et autres
Abstract Background: Despite advances in cancer genomics and immunotherapy, most cancer vaccine strategies target a limited set of canonical or mutated cancer antigens, capturing only a fraction of tumor antigenicity. Malignant cells generate a vast, largely unexplored repertoire of non-canonical “dark matter” …
jp, us
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Ryan Meng, Tarsem Lal Moudgil, Noriko Iwamoto, Yuriko Minegishi et autres
Background Recent studies have shown that the vast majority of a cancer’s neoantigens are not presented by MHC molecules, 1 2 offering a possible explanation for why clinical trials that successfully generated neoantigen-reactive T cells have not translated into improved clinical outcomes. …
us, jp
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Rom S. Leidner, Christopher C. Paustian, Shawn M. Jensen, Yoshinobu Koguchi et autres
Background DPV-001 is an off-the-shelf cancer vaccine containing tumor-associated proteins commonly overexpressed in adenocarcinoma and squamous cell carcinoma. It is enriched for short-lived proteins (SLiPs) and defective ribosomal products (DRiPs), including both canonical and non-canonical (or ‘dark matter’) antigens —comprising over 100 …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Christopher C. Paustian, Tarsem Lal Moudgil, Olivier Fesneau, Noah D. Simons et autres
Abstract Description Background Single cell RNA-seq combined with CITE-seq and TCR-seq has allowed for a deep characterization of anticancer immunity. Here we report on a single patient with head and neck squamous cell cancer (HNSCC) who underwent initial resection in 2020. Twenty-one …
in, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Tarsem Lal Moudgil, Traci L. Hilton, Olivier Fesneau, Yi-Ping Shih et autres
Abstract Description Background NCPs derived from non-coding regions of the genome are a recently discovered source of non-mutated HLA-presented cancer antigens. Here we studied the immune response of a patient with NSCLC that received adjuvant treatment with DPV-001 immunotherapy that contained canonical …
in, us, jp
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Olivier Fesneau, Kimberly A. Samson, Wesley K. Rosales, B. M. Jones et autres
Blockade of NKG2A/HLA-E interaction is a promising strategy to unleash the anti-tumor response. Yet the role of NKG2A+ CD8 T cells in the anti-tumor response and the regulation of NKG2A expression on human tumor-infiltrating T cells are still poorly understood. Here, by …
us
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Ryan Meng, Tarsem Lal Moudgil, Noriko Iwamoto, Yuriko Minegishi et autres
Background The rapidly growing field of immunopeptidomics has greatly expanded our understanding of the breadth of targets that T cells can potentially recognize on cancer cells. Non-canonical peptides (NCP) derived from non-coding or untranslated regions of the genome, along with peptides derived …
us, jp
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Rom S. Leidner, Christopher C. Paustian, Shawn M. Jensen, Tarsem Lal Moudgil et autres
Background DPV-001 is an off-the-shelf biologic containing proteins that are overexpressed by adenocarcinoma and squamous cell cancers. It is enriched for short-lived proteins (SLiPs) and defective ribosomal products (DRiPs), containing canonical and non-canonical alternative cancer neoantigens (dark matter, at least 30 microproteins) …
us, nl, jp
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Rom S. Leidner, Christopher C. Paustian, Shawn M. Jensen, Tarsem Lal Moudgil et autres
Abstract Background: Immune responses to shared cancer antigens have correlated with durable clinical responses. DPV-001 is a novel microvesicle vaccine that contains >300 proteins for genes commonly overexpressed by cancer and is enriched for short-lived proteins (SLiPs), and defective ribosomal products (DRiPs), …
us, jp
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Quyen Vu, Niyati Jhaveri, Aditya Pratapa, Christopher C. Paustian et autres
Background By integrating genomics, transcriptomics, proteomics, and metabolomics, researchers have gained unprecedented insights into the complex interplay between tumors and the immune system. This wealth of data has fueled the discovery of novel biomarkers for early cancer detection, prognostic stratification, and prediction …
us
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Christopher C. Paustian, Tarsem Lal Moudgil, Venkatesh Rajamanickam, Noah D. Simons et autres
Background Our group developed a strategy for generating an ‘off-the-shelf’ multivalent proteasome-blocked autophagosome vaccine that contains proteins for many genes commonly overexpressed in adenocarcinoma and squamous cell cancers. This strategy exploits in vitro manipulation of the antigen presentation pathway to concentrate the …
us, pr, jp
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Ryan Meng, Tarsem Lal Moudgil, Noriko Iwamoto, Yuriko Minegishi et autres
Background Short-lived proteins (SLiPs), defective ribosomal products (DRiPs), and Cancer’s dark matter/non-canonical peptides (NCP) are unstable and rapidly degraded, loaded onto MHC and represent a large proportion of the epitopes presented by cancer cells. Recent data suggests that NCP may play a …
us, jp
(code pays fourni par la source)